Biotech and Pharmaceuticals
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake | Reuters BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. The agreement will give Insilico […]
Read More
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove […]
Read More
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion to boost its oncology pipeline, the company said Wednesday. This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio before its best-selling cancer drug Keytruda loses key patent protection in 2028. […]
Read More
The price of menstrual products is skyrocketing from inflation, tariffs
Always products are displayed on a shelf in a supermarket in Sarajevo, Bosnia and Herzegovina October 29, 2024. Dado Ruvic | Reuters Rising inflation and ever-changing tariff policies have led to higher prices across store shelves over the past few years, squeezing consumers’ budgets. An often overlooked example: menstrual products. The average price of menstrual […]
Read More
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk‘s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from […]
Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]
Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]
Read More
Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market
HSBC analysts just slashed their recommendation on the world’s most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to dominate market narratives of the sector. Analysts led by Rajesh Kumar downgraded Lilly to Reduce from Hold, cutting their target price to $850 from $1,070, […]
Read More
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children. The move […]
Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]
Read More